UK-based drug research spinout Aquila Biomedical has been purchased by Concept Life Sciences, which hopes to enhance its own service offering to multiple scientific industries.
Aquila Biomedical, a UK-based drug research spinout from University of Edinburgh, was acquired yesterday by drug discovery company Concept Life Sciences for an undisclosed sum.
Aquila enables pharmaceutical developers to conduct pre-clinical research in fields such as oncology, multiple sclerosis and autoimmune disease.
The spinout claims that its procedures can markedly improve the likelihood of researchers identifying target compounds for further development.
Concept hopes that buying Aquila will strengthen its own offering, which includes services to the pharmaceutical industry as…
